Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $1,220.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target lifted by Barclays from $1,200.00 to $1,220.00 in a research note released on Friday, Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock.

A number of other research analysts have also recently weighed in on REGN. Truist Financial reiterated a buy rating and set a $1,200.00 price objective (up previously from $1,135.00) on shares of Regeneron Pharmaceuticals in a research report on Friday. Argus boosted their price objective on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a buy rating in a research report on Tuesday, June 25th. JPMorgan Chase & Co. boosted their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the company an overweight rating in a research report on Monday, June 17th. Bank of America boosted their target price on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an underperform rating in a research note on Friday, April 12th. Finally, Canaccord Genuity Group reissued a buy rating and set a $1,152.00 target price on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 27th. One analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of Moderate Buy and a consensus price target of $1,097.05.

Regeneron Pharmaceuticals Trading Down 1.0 %

REGN stock traded down $10.95 during mid-day trading on Friday, reaching $1,082.19. 646,247 shares of the stock traded hands, compared to its average volume of 415,793. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.96. Regeneron Pharmaceuticals has a one year low of $759.15 and a one year high of $1,115.00. The stock has a market capitalization of $119.25 billion, a PE ratio of 31.97, a PEG ratio of 2.34 and a beta of 0.13. The business has a 50-day moving average price of $1,043.43 and a two-hundred day moving average price of $982.47.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The firm had revenue of $3.15 billion for the quarter, compared to the consensus estimate of $3.19 billion. Equities research analysts expect that Regeneron Pharmaceuticals will post 37.38 EPS for the current year.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 1,172 shares of the business’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $974.86, for a total value of $1,142,535.92. Following the completion of the transaction, the director now directly owns 1,382 shares in the company, valued at $1,347,256.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, EVP Joseph J. Larosa sold 1,866 shares of the company’s stock in a transaction dated Thursday, July 11th. The shares were sold at an average price of $1,088.95, for a total transaction of $2,031,980.70. Following the transaction, the executive vice president now owns 37,937 shares in the company, valued at $41,311,496.15. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Michael S. Brown sold 1,172 shares of the company’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $974.86, for a total transaction of $1,142,535.92. Following the transaction, the director now owns 1,382 shares in the company, valued at approximately $1,347,256.52. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 65,074 shares of company stock worth $64,546,123. 7.48% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. West Paces Advisors Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 575.0% during the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 23 shares in the last quarter. Stephens Consulting LLC acquired a new position in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $26,000. Crewe Advisors LLC acquired a new position in Regeneron Pharmaceuticals in the 1st quarter worth approximately $28,000. MCF Advisors LLC increased its holdings in Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 12 shares during the period. Finally, Lynx Investment Advisory acquired a new position in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $33,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.